Recurrent Intraocular Inflammation after Faricimab and Aflibercept 8 mg despite Intervening Tolerance of Aflibercept 2 mg: A Case Report and Literature Review
This case report describes a patient with neovascular age-related macular degeneration who experienced recurrent noninfectious intraocular inflammation following both faricimab and aflibercept 8 mg, despite tolerating intervening doses of aflibercept 2 mg and earlier aflibercept 8 mg injections, highlighting the need for continued vigilance when escalating anti-VEGF therapy in eyes with prior drug-associated inflammation.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Inside the eye, a delicate balance keeps vision sharp. When this balance is disrupted by a condition called neovascular age-related macular degeneration, tiny, fragile blood vessels grow where they should not, leaking fluid and damaging the central part of the retina responsible for fine detail. To stop this, doctors inject medicine directly into the eye. These medicines work by blocking a specific protein that signals these harmful vessels to grow. For years, doctors have relied on a standard dose of this medicine, but for some patients, the effect wears off too quickly, or the fluid returns before the next scheduled visit. To solve this, scientists developed stronger versions of the drug, including a high-dose injection that lasts longer and a newer type of drug that blocks two different growth signals at once. The goal was simple: keep the eye dry and clear for longer periods with fewer injections.
However, a new challenge has emerged. While these powerful drugs are effective at stopping the leaking vessels, they can sometimes trigger the eye's immune system to react, causing inflammation. This swelling inside the eye, known as intraocular inflammation, can blur vision and, if severe, threaten sight. Doctors face a difficult choice when this happens: stop the treatment and risk the disease returning, or try a different drug and hope the eye tolerates it. The question is whether an eye that reacts badly to one type of medicine will also react to another, especially when switching to a higher dose.
A recent case report from South Korea describes a patient who faced this exact dilemma, revealing a pattern of reaction that doctors had not seen before. The patient, a 62-year-old woman, had been treated for years with a standard drug called bevacizumab without any issues. When her doctors switched her to the newer, dual-action drug to get better control, her vision suddenly dropped three days after her third injection. An examination showed that while the front part of her eye was calm, the jelly-like substance filling the back of the eye had become cloudy with cells, a sign of inflammation. After treating her with steroids, her vision recovered, but the doctors decided to stop using that drug.
They then tried a standard dose of the high-dose drug, aflibercept. This time, the inflammation did not return, and her eye tolerated the shot well. However, the treatment was not strong enough; fluid began to build up again under the retina, and the doctors could not keep the long intervals between shots that they wanted. They had to make a difficult decision: escalate to the full, high dose of aflibercept to save her vision, even though she had just had a bad reaction to a different drug.
The first two injections of this high dose went smoothly. Her vision remained steady, and her eye showed no signs of swelling. But then, after the third injection of the high dose, the same problem returned. Just two days later, her vision plummeted again. By the fourth day, the front of her eye was still quiet, but the back of the eye was once again filled with significant cloudiness. It was a clear sign that her eye had reacted to the high dose, despite having tolerated the lower dose and the first two shots of the high dose without issue.
This sequence of events is unusual. In previous reports, patients who reacted to the newer drug often reacted immediately when switched directly to the high dose of the other drug. Here, the patient had a long break in between, tolerated a lower dose, and even handled the first two high-dose shots. The inflammation only appeared after the third high-dose injection. This suggests that an eye can appear to be safe and tolerant for a while, only to develop a reaction later. The researchers noted that the inflammation in this case was primarily located in the back of the eye, rather than the front, which is a specific detail that helps doctors recognize the pattern.
The study concludes that for patients who have had inflammation with one of these drugs, switching to a high dose of another does not guarantee safety, even if the eye seems fine at first. The fact that the patient tolerated the lower dose and the first two high doses does not mean the risk has disappeared. The doctors suggest that anyone with a history of this kind of reaction needs to be watched very closely after every single injection, regardless of how well the previous shots went. It is a reminder that the eye's immune system can be unpredictable, and what works for a while might eventually cause a problem, requiring constant vigilance to protect vision.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.